JP2024530954A - アトピー性皮膚炎の処置 - Google Patents

アトピー性皮膚炎の処置 Download PDF

Info

Publication number
JP2024530954A
JP2024530954A JP2024508382A JP2024508382A JP2024530954A JP 2024530954 A JP2024530954 A JP 2024530954A JP 2024508382 A JP2024508382 A JP 2024508382A JP 2024508382 A JP2024508382 A JP 2024508382A JP 2024530954 A JP2024530954 A JP 2024530954A
Authority
JP
Japan
Prior art keywords
antibody
injection
administration
fragment
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530954A5 (https=
JPWO2023017252A5 (https=
Inventor
ベン・ポーター－ブラウン
ソニア・クアラティーノ
リチャード・シー・エー・セインソン
ジョン・パウエル
Original Assignee
カイマブ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2115152.7A external-priority patent/GB202115152D0/en
Priority claimed from GBGB2204211.3A external-priority patent/GB202204211D0/en
Priority claimed from GBGB2204291.5A external-priority patent/GB202204291D0/en
Application filed by カイマブ・リミテッド filed Critical カイマブ・リミテッド
Publication of JP2024530954A publication Critical patent/JP2024530954A/ja
Publication of JP2024530954A5 publication Critical patent/JP2024530954A5/ja
Publication of JPWO2023017252A5 publication Critical patent/JPWO2023017252A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024508382A 2021-08-10 2022-08-09 アトピー性皮膚炎の処置 Pending JP2024530954A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB202111492 2021-08-10
GB2111492.1 2021-08-10
GBGB2115152.7A GB202115152D0 (en) 2021-10-21 2021-10-21 Treatment of atopic dermatitis
GB2115152.7 2021-10-21
GB2204211.3 2022-03-24
GBGB2204211.3A GB202204211D0 (en) 2022-03-24 2022-03-24 Treatment of atopic dermatitis
GB2204291.5 2022-03-25
GBGB2204291.5A GB202204291D0 (en) 2022-03-25 2022-03-25 Treatment of atopic dermatitis
PCT/GB2022/052070 WO2023017252A1 (en) 2021-08-10 2022-08-09 Treatment of atopic dermatitis

Publications (3)

Publication Number Publication Date
JP2024530954A true JP2024530954A (ja) 2024-08-27
JP2024530954A5 JP2024530954A5 (https=) 2025-08-19
JPWO2023017252A5 JPWO2023017252A5 (https=) 2025-08-19

Family

ID=82942548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508382A Pending JP2024530954A (ja) 2021-08-10 2022-08-09 アトピー性皮膚炎の処置

Country Status (11)

Country Link
US (2) US20230235069A1 (https=)
EP (1) EP4384270A1 (https=)
JP (1) JP2024530954A (https=)
KR (1) KR20240043789A (https=)
AR (1) AR126749A1 (https=)
AU (1) AU2022326849A1 (https=)
CA (1) CA3228708A1 (https=)
IL (1) IL310701A (https=)
MX (1) MX2024001877A (https=)
TW (1) TW202330023A (https=)
WO (1) WO2023017252A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260026080A (ko) * 2023-06-20 2026-02-25 키맵 리미티드 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025233445A1 (en) * 2024-05-08 2025-11-13 Kymab Limited Treatment of head and neck atopic dermatitis
WO2025255353A1 (en) * 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519718A (ja) * 2005-12-16 2009-05-21 ジェネンテック・インコーポレーテッド 抗ｏｘ４０ｌ抗体とその使用方法
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
JP2017513813A (ja) * 2014-03-04 2017-06-01 カイマブ・リミテッド 抗体、使用、及び方法
JP2017523984A (ja) * 2014-08-04 2017-08-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519718A (ja) * 2005-12-16 2009-05-21 ジェネンテック・インコーポレーテッド 抗ｏｘ４０ｌ抗体とその使用方法
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
JP2017513813A (ja) * 2014-03-04 2017-06-01 カイマブ・リミテッド 抗体、使用、及び方法
JP2017523984A (ja) * 2014-08-04 2017-08-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ID NCT03754309, VERSION 14: 2021-04-30 [オンライン], JPN6025034555, 30 April 2021 (2021-04-30), pages 1 - 7, ISSN: 0005672971 *
CLINICALTRIALS.GOV ID NCT04449939, VERSION 3: 2020-12-17 [オンライン], JPN6025034556, pages 1 - 6, ISSN: 0005672972 *
KYMAB ANNOUNCES POSITIVE PHASE 2A RESULTS FOR KY1005 IN MODERATE TO SEVERE ATOPIC DERMATITIS, [ONLIN, JPN6025034554, 11 August 2020 (2020-08-11), ISSN: 0005818565 *

Also Published As

Publication number Publication date
EP4384270A1 (en) 2024-06-19
US20230235069A1 (en) 2023-07-27
AR126749A1 (es) 2023-11-08
TW202330023A (zh) 2023-08-01
MX2024001877A (es) 2024-02-28
WO2023017252A1 (en) 2023-02-16
IL310701A (en) 2024-04-01
US20250353918A1 (en) 2025-11-20
AU2022326849A1 (en) 2024-03-21
CA3228708A1 (en) 2023-02-16
KR20240043789A (ko) 2024-04-03

Similar Documents

Publication Publication Date Title
US20230293683A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
JP2024530954A (ja) アトピー性皮膚炎の処置
US20240018249A1 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising il-31 antagonist as active ingredient
JP2025106377A (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
KR20220044563A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20250136676A1 (en) Treatment Of Chronic Obstructive Pulmonary Disease With An Anti-Interleukin-33 Antibody
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
IL277474B1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
JP2025527762A (ja) 抗インターロイキン－３３抗体を用いた喘息の治療
CN118488851A (zh) 特应性皮炎的治疗
RU2847150C1 (ru) Применение антагониста il-18 для лечения и/или предупреждения атопического дерматита или связанного с ним состояния
RU2783540C2 (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
US20250059289A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
WO2026047072A1 (en) Medical use
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317